Role of targeted therapy in metastatic colorectal cancer

doi:10.4251/wjgo.v8.i9.642

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 9

This Article

(369)

(439)

(0)

(11140)

(76)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastrointest Oncol. Sep 15, 2016; 8(9): 642-655
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.642

Table 2 Clinical trials of anti-epidermal growth factor receptor therapies in metastatic colorectal cancer with KRAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
CRYSTAL	FOLFIRI + Cetuximab	316	57.3%	9.9	23.5
OPUS	FOLFOX + Cetuximab	159	57%	8.3	22.8
COIN	FOLFOX/CapeOX + Cetuximab	362	64%	8.6	17.0
NORDIC-VII	FLOX + Cetuximab	97	46%	7.9	20.1
PRIME	FOLFOX + Panitumumab	325	55%	9.6	23.9
Second-line, salvage-line chemotherapy, or beyond progression
20050181 trial	FOLFIRI + Panitumumab	303	36%	6.7	14.5
PICCOLO	Irinotecan + Panitumumab	230	34%	5.5	10.4
CO.17	Cetuximab	117	13%	3.7	9.5
20020408 trial	Panitumumab	124	17%	12.3 wk	8.1

ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin; CapeOX: Capecitabine/oxaliplatin; FLOX: Bolus 5-fluorouracil/leucovorin/oxaliplatin.

Full Size Table

Citation: Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
URL: https://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i9.642

Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655 [PMID: 27672422 DOI: 10.4251/wjgo.v8.i9.642]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.